The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases

Biochemical Journal

Volumn 465, Issue , 2015, Pages 271-279

  Ozanne, James ^a   Prescott, Alan R ^b   Clark, Kristopher ^a  

^a MRC Protein Phosphorylation Unit   (United Kingdom)

^b Sir James Black Centre   (United Kingdom)

Author keywords

Bosutinib; Chemical biology; Dasatinib; Inflammation; Interleukin 10; Salt inducible kinase

Indexed keywords

ARGINASE 1; BOSUTINIB; CREB REGULATED TRANSCRIPTION CO ACTIVATOR 3 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 6; LAPATINIB; LIGHT ENZYME; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NURR77 PROTEIN; PROTEIN; PROTEIN C FOS; PROTEIN TYROSINE KINASE; SALT INDUCIBLE KINASE 2; SALT INDUCIBLE KINASE 3; SPHINGOSINE KINASE 1; SUNITINIB; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANDETANIB; ANILINE DERIVATIVE; ARG1 PROTEIN, MOUSE; ARGINASE; CREB1 PROTEIN, MOUSE; CRTC3 PROTEIN, MOUSE; CYTOKINE; HERPESVIRUS ENTRY MEDIATOR LIGAND; NITRILE; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SALT-INDUCIBLE KINASE-2, MOUSE; SPHINGOSINE KINASE; THIAZOLE DERIVATIVE; TNFSF14 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; GENETIC TRANSCRIPTION; IC50; MACROPHAGE; MOUSE; NONHUMAN; POLARIZATION; PROTEIN DEPHOSPHORYLATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; INNATE IMMUNITY;

ANILINE COMPOUNDS; ANIMALS; ARGINASE; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOKINES; DASATINIB; IMMUNITY, INNATE; MACROPHAGES; MICE; NITRILES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; QUINOLINES; THIAZOLES; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 84920577517     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20141165     Document Type: Article

References (41)

1. Serhan, C. N. and Savill, J. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6, 1191-1197
2. Sica, A. and Mantovani, A. (2012) Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795
3. Martinez, F. O. and Gordon, S. (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000 Prime Rep. 6, 13
4. Mosser, D. M. and Edwards, J. P. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969
5. Edwards, J. P., Zhang, X., Frauwirth, K. A. and Mosser, D. M. (2006) Biochemical and functional characterization of three activated macrophage populations. J. Leuk. Biol. 80, 1298-1307
6. Nair, M. G., Cochrane, D. W. and Allen, J. E. (2003) Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunol. Lett. 85, 173-180
7. Gerber, J. S. and Mosser, D. M. (2001) Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J. Immunol. 166, 6861-6868
8. Fleming, B. D. and Mosser, D. M. (2011) Regulatory macrophages: setting the threshold for therapy. Eur. J. Immunol. 41, 2498-2502
9. Kawai, T. and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384
10. Clark, K. (2014) Protein kinase networks that limit TLR signalling. Biochem. Soc. Trans. 42, 11-24
11. Hu, X., and Paik., P. K., Chen, J., Yarilina, A., Kockeritz, L., and Lu., T. T., Woodgett, J. R. and Ivashkiv, L. B. (2006) IFN-γ suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24, 563-574
12. 2 induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J. Immunol. 190, 565-577
13. Clark, K., and MacKenzie., K. F., Petkevicius, K., Kristariyanto, Y., Zhang, J., and Choi., H. G., Peggie, M., Plater, L., Pedrioli, P. G., McIver, E. et al. (2012) Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl. Acad. Sci. U.S.A. 109, 16986-16991
14. Trela, E., Glowacki, S. and Blasiak, J. (2014) Therapy of chronic myeloid leukemia: twilight of the imatinib era? ISRN Oncol. 2014, 596483
15. Pfaffl, M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45
16. Hastie, C. J., McLauchlan, H. and Cohen, P. (2006) Assay of protein kinases using radiolabeled ATP: a protocol. Nat. Protoc. 1, 968-971
17. Bain, J., Plater, L., Elliott, M., Shpiro, N., and Hastie., C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R. and Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315
18. Ananieva, O., Darragh, J., Johansen, C., Carr, J. M., McIlrath, J., Park, J. M., Wingate, A., Monk, C. E., Toth, R., Santos, S. G. et al. (2008) The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat. Immunol. 9, 1028-1036
19. Altarejos, J. Y. and Montminy, M. (2011) CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat. Rev. Mol. Cell Biol. 12, 141-151
20. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C. et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044
21. Fraser, C. K., and Lousberg., E. L., Kumar, R., Hughes, T. P., Diener, K. R. and Hayball, J. D. (2009) Dasatinib inhibits the secretion of TNF-α following TLR stimulation in vitro and in vivo. Exp. Hematol. 37, 1435-1444
22. Hantschel, O., Rix, U., Schmidt, U., Burckstummer, T., Kneidinger, M., Schutze, G., Colinge, J., and Bennett., K. L., Ellmeier, W., Valent, P. et al. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. U.S.A. 104, 13283-13288
23. Futosi, K., Nemeth, T., Pick, R., Vantus, T., Walzog, B. and Mocsai, A. (2012) Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 119, 4981-4991
24. Kneidinger, M., Schmidt, U., Rix, U., Gleixner, K. V., Vales, A., Baumgartner, C., Lupinek, C., Weghofer, M., Bennett, K. L., Herrmann, H. et al. (2008) The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 111, 3097-3107
25. Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Muller, A., Baumgartner, C., Valent, P., Augustin, M. et al. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23, 477-485
26. Anastassiadis, T., and Deacon., S. W., Devarajan, K., Ma, H. and Peterson, J. R. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039-1045
27. Davis, M. I., and Hunt., J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K. and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046-1051
28. Luan, B., and Goodarzi., M. O., Phillips, N. G., Guo, X., Chen, Y. D., Yao, J., Allison, M., and Rotter., J. I., Shaw, R. and Montminy, M. (2014) Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4. Cell Metab. 19, 1058-1065
29. Piao, W., Song, C., Chen, H., Wahl, L. M., Fitzgerald, K. A., O'Neill, L. A. and Medvedev, A. E. (2008) Tyrosine phosphorylation of MyD88 adapter-like (Mal) is critical for signal transduction and blocked in endotoxin tolerance. J. Biol. Chem. 283, 3109-3119
30. Medvedev, A. E., Piao, W., Shoenfelt, J., Rhee, S. H., Chen, H., Basu, S., and Wahl., L. M., Fenton, M. J. and Vogel, S. N. (2007) Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J. Biol. Chem. 282, 16042-16053
31. Lee, K. G., Xu, S., Kang, Z. H., Huo, J., Huang, M., Liu, D., Takeuchi, O., Akira, S. and Lam, K. P. (2012) Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc. Natl. Acad. Sci. U.S.A. 109, 5791-5796
32. Horwood, N. J., Mahon, T., McDaid, J. P., Campbell, J., Mano, H., and Brennan., F. M., Webster, D. and Foxwell, B. M. (2003) Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor α production. J. Exp. Med. 197, 1603-1611
33. Das, J., Chen, P., Norris, D., Padmanabha, R., Lin, J., Moquin, R. V., Shen, Z., Cook, L. S., Doweyko, A. M., Pitt, S. et al. (2006) 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49, 6819-6832
34. Jung, S. H., Sun, X., Ryu, W. S. and Yang, B. S. (2013) Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice. Br. J. Dermatol. 168, 112-119
35. Dhawan, G. and Combs, C. K. (2012) Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. J. Neuroinflammation 9, 117
36. Park, J., and Yoon., Y. S., Han, H. S., Kim, Y. H., Ogawa, Y., Park, K. G., Lee, C. H., Kim, S. T. and Koo, S. H. (2014) SIK2 is critical in the regulation of lipid homeostasis and adipogenesis in vivo. Diabetes 63, 3659-3673
37. Sakamaki, J., Fu, A., Reeks, C., Baird, S., Depatie, C., Al Azzabi, M., Bardeesy, N., Gingras, A. C., Yee, S. P. and Screaton, R. A. (2014) Role of the SIK2-p35-PJA2 complex in pancreatic β-cell functional compensation. Nat. Cell Biol. 16, 234-244
38. Bricambert, J., Miranda, J., Benhamed, F., Girard, J., Postic, C. and Dentin, R. (2010) Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J. Clin. Invest. 120, 4316-4331
39. Breccia, M., Muscaritoli, M., Cannella, L., Stefanizzi, C., Frustaci, A. and Alimena, G. (2008) Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk. Res. 32, 1626-1628
40. Ono, K., Suzushima, H., Watanabe, Y., Kikukawa, Y., Shimomura, T., Furukawa, N., Kawaguchi, T. and Araki, E. (2012) Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Intern. Med. 51, 2763-2766
41. Lumeng, C. N. and Saltiel, A. R. (2011) Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111-2117